Company: NDRA
Filing Date: 2025-10-30
Form Type: 424B5
Source: 0001213900-25-103705
Chunk: 46

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-10-30
Form: 424B5
Chunk 46
---
07% from 2022 to 2030, according to Grand View Research.
Ultrasound systems are relatively inexpensive compared to CT and MRI systems, as smaller portable ultrasound systems can cost as little
as approximately $5,000 and the price of new cart-based ultrasound systems can range from approximately $75,000 to $200,000. These numbers
include both portable and cart-based ultrasound systems, and cover all types of diagnostic ultrasound procedures, including systems intended
for cardiology, prenatal and abdominal use. We do not currently intend to address cart-based ultrasound systems focused on applications
in prenatal care, nor certain portable ultrasound applications such as emergency room medicine, where we believe our TAEUS technology
may not substantially impact patient care. Accordingly, we estimate the addressable market for one or more of our current or future TAEUS
applications to include approximately 700,000 ultrasound systems currently in use throughout the world, in addition to other types of
capital equipment.

To demonstrate the capabilities of our TAEUS platform,
we have conducted various internal ex-vivo laboratory experiments and limited internal in-vivo large animal studies. In our ex-vivo and
in-vivo testing, we have demonstrated that the TAEUS platform has the following capabilities and potential clinical applications:

| ● | Tissue Composition: Our TAEUS technology enables ultrasound to distinguish fat from lean tissue. This capability would enable the              
 use of TAEUS-enhanced ultrasound for the early identification, staging and monitoring of NAFLD, a precursor to NASH, liver fibrosis, cirrhosis 
 and liver cancer.                                                                                                                              |

| ● | Temperature Monitoring: Our TAEUS technology enables traditional ultrasound to visualize changes in tissue temperature, in real time.        
 This capability would enable the use of TAEUS-enhanced ultrasound to guide thermoablative therapy, which uses heat or cold to affect tissue, 
 such as in the treatment of cardiac atrial fibrillation, or removal of cancerous liver and kidney lesions, with greater accuracy, and        
 perform cosmetology procedures such as lipolysis of abdominal fat.                                                                           |

| ● | Vascular Imaging: Our TAEUS technology has the potential to enable visualization of blood vessels from any angle, using only a saline 
 solution contrasting agent, unlike Doppler ultrasound, which requires precise viewing angles. This capability would enable the use of 
 TAEUS-enhanced ultrasound to assist in identifying arterial plaques or malformed vessels.                                             |

| ● | Tissue Perfusion: Our TAEUS technology